Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Li‐Tzong Chen et al.|New England Journal of Medicine|2023Cited by 530
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic CancerThomas B. Karasic, Peter J. O’Dwyer, Mark H. O’Hara et al.|JAMA Oncology|2019Cited by 289
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A. Reiss, Susan M. Domchek, Rosemarie Mick et al.|Journal of Clinical Oncology|2021Cited by 238
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A. Reiss, Robert H. Vonderheide, Rosemarie Mick et al.|The Lancet Oncology|2022Cited by 137
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal CancerThomas B. Karasic, Peter J. O’Dwyer, Timothy J. Brown et al.|The Oncologist|2022Cited by 33